The authors of a systematic review and meta-analysis recommended reconsideration of guidelines on sodium-glucose cotransporter-2 (SGLT-2) inhibitors to increase use among patients at risk of cardiovascular disease.
They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).
In a recent study, a serum C-peptide testing program resulted in reclassification of the cause of diabetes in about 7% of the cohort tested at one diabetes center in Scotland. Reclassification was most likely in those diagnosed at age 30 years or
A pooled analysis of three randomized clinical trials found reductions in major adverse cardiac or cerebrovascular events after percutaneous coronary intervention (PCI) at 3.9-year follow-up only in patients with low-density lipoprotein (LDL)
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement
The authors of the retrospective study called for additional research on the pathogenesis of acute kidney injury (AKI) and the associated risk factors, such as medications, in diabetic patients.
Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with
Continuous glucose monitoring (CGM) was associated with improved HbA1c levels among adolescents and young adults in one trial and less hypoglycemia among older adults in another.